Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

Kymera Therapeutics (NASDAQ:KYMR) rose ~16% in after-hours trading Friday after the company announced it would release phase 1 data of its inflammatory diseases oral candidate KT-621 in healthy ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

BioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with motixafortide combination.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

--On pace for largest percent decrease since Oct. 27, 2023, when it fell 19.13% --Down 9.68% month-to-date; on pace for worst month since Oct. 2023, when it fell 15.64% --Down 16.48% from its all-time ...

(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.